Kobayashi Pharmaceutical Co Ltd (JP:4967)
:4967
Want to see JP:4967 full AI Analyst Report?
Top Page
Kobayashi Pharmaceutical Co
(4967)
Select Model
Select Model
Rating:65Neutral
Price Target:
¥5,952.00
▲(10.88% Upside)
Action:Reiterated
Date:02/18/26
The score is primarily supported by a very strong, low-debt balance sheet and improving 2025 cash generation, alongside moderately positive price momentum. Offsetting these positives are the sharp deterioration in profitability since 2023 and a very high P/E valuation.
Positive Factors
Conservative balance sheet
Minimal debt and large stable equity provide durable financial resilience. Low leverage reduces solvency risk, preserves borrowing capacity for capex or M&A, and supports ongoing operations and payouts during cyclical weakness, strengthening strategic optionality over months.
Negative Factors
Sharp profitability deterioration
A steep multi-year decline in net income signals material margin pressure and weakening operating performance. Persistently lower profits constrain reinvestment, limit flexibility on pricing or promotions, and erode long-term returns unless structural cost or revenue drivers are restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Minimal debt and large stable equity provide durable financial resilience. Low leverage reduces solvency risk, preserves borrowing capacity for capex or M&A, and supports ongoing operations and payouts during cyclical weakness, strengthening strategic optionality over months.
Read all positive factors
Kobayashi Pharmaceutical Co (4967) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥421.25B
Dividend Yield1.95%
Average Volume (3M)221.72K
Price to Earnings (P/E)137.4
Beta (1Y)0.29
Revenue Growth3.14%
EPS Growth-71.37%
CountryJP
Employees3,615
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)158.72
Shares Outstanding78,050,000
10 Day Avg. Volume218,190
30 Day Avg. Volume221,720
Financial Highlights & Ratios
PEG Ratio-1.73
Price to Book (P/B)1.91
Price to Sales (P/S)2.43
P/FCF Ratio32.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,200.00Price Target Upside-3.13% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)141.69
Revenue Forecast (FY)¥173.25B
Kobayashi Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company provides products in the areas of healthcare, skincare, body warmer, and household. It also offe...
How the Company Makes Money
Kobayashi Pharmaceutical Co., Ltd. generates revenue primarily through the sale of its over-the-counter (OTC) medications, household products, and personal care goods. The company markets a diverse portfolio of products that target everyday health...
Kobayashi Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
92
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 161.48B | 165.74B | 165.60B | 173.46B | 166.26B | 155.25B |
| Gross Profit | 82.99B | 84.71B | 87.60B | 96.38B | 92.33B | 88.77B |
| EBITDA | 23.61B | 12.52B | 21.96B | 33.65B | 33.33B | 32.49B |
| Net Income | 11.80B | 3.66B | 10.07B | 20.34B | 20.02B | 19.71B |
Balance Sheet | ||||||
| Total Assets | 260.71B | 275.33B | 265.37B | 267.47B | 255.83B | 252.55B |
| Cash, Cash Equivalents and Short-Term Investments | 69.67B | 70.61B | 65.75B | 79.84B | 104.53B | 109.05B |
| Total Debt | 749.00M | 678.00M | 846.00M | 987.00M | 792.00M | 630.00M |
| Total Liabilities | 52.47B | 64.32B | 51.89B | 62.66B | 57.93B | 56.95B |
| Stockholders Equity | 208.24B | 211.00B | 213.47B | 204.82B | 197.90B | 195.60B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 12.34B | -14.81B | 5.60B | 17.17B | 18.76B |
| Operating Cash Flow | 0.00 | 25.59B | 11.25B | 18.36B | 31.91B | 22.42B |
| Investing Cash Flow | 0.00 | -154.00M | -18.41B | -19.58B | -14.31B | 7.99B |
| Financing Cash Flow | 0.00 | -7.92B | -7.77B | -19.46B | -20.76B | -10.38B |
Kobayashi Pharmaceutical Co Technical Analysis
Negative
5368.00
Price Trends
5852.12
Negative
5694.54
Negative
5486.73
Positive
Market Momentum
-27.97
Positive
40.10
Neutral
22.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4967, the sentiment is Negative. The current price of 5368 is below the 20-day moving average (MA) of 5821.60, below the 50-day MA of 5852.12, and below the 200-day MA of 5486.73, indicating a neutral trend. The MACD of -27.97 indicates Positive momentum. The RSI at 40.10 is Neutral, neither overbought nor oversold. The STOCH value of 22.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4967.
Kobayashi Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥539.65B | 15.80 | 12.66% | 1.53% | 11.37% | 11.35% | |
69 Neutral | ¥304.65B | 29.61 | 2.72% | 2.61% | 1.63% | 74.87% | |
65 Neutral | ¥421.25B | 137.43 | 5.37% | 1.95% | 3.14% | -71.37% | |
64 Neutral | ¥2.71T | 20.85 | 11.50% | 2.41% | 3.60% | 13.80% | |
64 Neutral | ¥425.96B | 15.72 | 9.09% | 1.73% | 3.10% | 27.99% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
52 Neutral | ¥1.03T | -28.86 | ― | 2.11% | 0.45% | -836.50% |
* Consumer Defensive Sector Average
JP:4967
Kobayashi Pharmaceutical Co
5,627.00
298.35
5.60%
JP:4452
Kao
5,847.00
-647.94
-9.98%
JP:4922
Kose
5,284.00
-543.62
-9.33%
JP:4912
Lion
1,577.50
64.53
4.27%
JP:4527
Rohto Pharmaceutical Co
2,349.50
397.64
20.37%
JP:4911
Shiseido Company,Limited
2,517.50
133.72
5.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.